

## Pathology Associates announces the launch of UroVysion(FISH)

Pathology Associates continues to research and employ new testing processes to ensure you are getting the very best possible diagnosis when sending your patient samples to us. As part of that professional commitment, we are introducing to our clinician partners a new prognostic tool for recurrent bladder cancer—one about which we are certain you are already hearing a great deal—the Vysis® UroVysion Bladder Cancer Recurrence Test (UroVysion Kit).

The UroVysion test examines cell DNA directly to detect cancer-associated genetic abnormalities, often times well in advance of detectable morphologic changes. The direct analysis of genetic change means less subjectivity in recurrence detection. Less subjectivity leads to more accurate monitoring of your bladder cancer and delivers more valuable information for therapeutic decisions. The right treatment at the right time means a better quality of life.

Specifically, the UroVysion Test is . . .

- The first Cellular Genomics-based test for monitoring the recurrence of bladder cancer - utilizing genomic DNA-probes and Vysis' proprietary fluorescence probe technology.
- A Non-invasive urine test - cells for analysis may be harvested from voided urine. As few as **four** cells with certain genetic changes are required for a successful study.
- The only FDA cleared test for use as an in vitro diagnostic (IVD) product to detect the recurrence of bladder cancer in conjunction with cystoscopy. It is not intended to replace your cystoscopy studies; instead, it will serve to highlight patients of concern or provide considerable insight into patients showing good response to therapy.
- Highly sensitive for the detection of higher stage, higher grade bladder cancer tumors showing 100% sensitive for stage T2 and Tis tumors and 94% sensitive for grade 3 tumors. High sensitivity means fewer false negatives.
- Highly specific for cancer cells. In 275 patients (59 normal volunteers and 216 non-healthy subjects), the UroVysion Kit showed 94.5% specificity. In healthy volunteers (smokers and non-smokers over age 50), the specificity was 100%. High specificity means fewer false positive results.
- Unaffected by (BCG) intravesical therapy, other therapies, infections, hematuria, or benign prostatic hyperplasia.
- Readily reimbursed by private and public payers.
- A 4-probe FISH study designed to detect aneuploidy of chr 3,7,17 and deletion of the 9p21 locus. The 9p21 locus is the location for the p16 tumor suppressor gene.

## **When to Use UroVysion(FISH)**

- 1.) High Risk Hematuria**
- 2.) High Risk Recurrence Cases such as**

**High Grade Tumors**

**Multi-Focal Tumors**

**History Rapid Recurrences**

**History Multiple Recurrences**

- 3.) Clarify Equivocal Cytology Results**
- 4.) Clarify NMP-22 Results**
- 5.) Annually on Low Grade Patients**

**Detect the -5% that progress to High Grade**

**-5% Concurrent with CIS**

- 6.) Monitor Response to Intravesical Therapy**

We are confident you will find this study adds increased sensitivity and sensitivity for the early detection of recurrent bladder cancer. We look forward to discussing this with you in greater detail and to serving you in this and all of your pathology needs.

If you have any further questions please visit us at [www.pathology-associates.com](http://www.pathology-associates.com) or call us at (559)326-2849.